UroGen Pharma (URGN) Return on Capital Employed Growth (5y) (2023 - 2026)
UroGen Pharma (URGN) Return on Capital Employed Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | UroGen Pharma | 2.03 Bn | 1.89 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,195.00 |
| Dec 31, 2025 | 3,040.00 |
| Sep 30, 2025 | 1,859.00 |
| Jun 30, 2025 | 2,215.00 |
| Mar 31, 2025 | 2,564.00 |
| Dec 31, 2024 | 1,707.00 |
| Sep 30, 2024 | 1,053.00 |
| Jun 30, 2024 | 60.00 |
| Mar 31, 2024 | 887.00 |
| Dec 31, 2023 | 3,924.00 |
| Sep 30, 2023 | -139.00 |
| Jun 30, 2023 | -6,174.00 |
| Mar 31, 2023 | -4,889.00 |